|
Market Closed -
Nasdaq Stockholm
17:00:00 13/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 0.8480 SEK | +36.77% |
|
-58.63% | -56.95% |
| 11-13 | Irlab narrows operating loss | FW |
| 11-13 | IRLAB Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
Business description: IRLAB Therapeutics AB

Number of employees: 31
Sales by Activity: IRLAB Therapeutics AB
| Fiscal Period: December | 2021 (SEK) | 2022 (SEK) | 2023 (SEK) | 2024 (SEK) | 2025 (SEK) |
|---|---|---|---|---|---|
Pharmaceuticals | 208M | 61.14M | 5.68M | 94.63M | 57.46M |
Geographical breakdown of sales: IRLAB Therapeutics AB
| Fiscal Period: December | 2021 (SEK) | 2022 (SEK) | 2023 (SEK) | 2024 (SEK) | 2025 (SEK) |
|---|---|---|---|---|---|
United States | - | - | 4.22M | 94.63M | 57.46M |
United Kingdom | 208M | 61.14M | 1.46M | - | - |
Executive Committee: IRLAB Therapeutics AB
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/07/2024 | |
Susanna Waters
PRN | Corporate Officer/Principal | 60 | 31/12/2012 |
Clas Sonesson
CTO | Chief Tech/Sci/R&D Officer | 65 | 31/12/2015 |
Nicholas Waters
CEO | Chief Executive Officer | 64 | 31/12/2012 |
Gustaf Albért
DFI | Director of Finance/CFO | 58 | 16/11/2025 |
Composition of the Board of Directors: IRLAB Therapeutics AB
| Director | Title | Age | Since |
|---|---|---|---|
Rein Piir
BRD | Director/Board Member | 68 | 31/12/2015 |
| Chairman | 73 | 06/05/2020 | |
Veronica Wallin
BRD | Director/Board Member | 40 | 31/12/2022 |
| Chairman | - | 24/09/2026 | |
James Gamgort
BRD | Director/Board Member | 59 | 04/06/2026 |
Company details: IRLAB Therapeutics AB

Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +36.77% | -58.63% | -63.45% | -86.95% | 12.52M | ||
| +1.26% | +6.61% | +40.79% | +136.32% | 1,286B | ||
| +0.79% | +3.45% | +45.84% | +93.52% | 688B | ||
| +0.20% | +1.28% | +26.97% | +113.70% | 521B | ||
| -0.44% | +3.69% | +41.45% | +68.91% | 386B | ||
| +0.55% | +0.70% | +59.02% | +44.62% | 364B | ||
| -0.12% | +0.74% | +28.39% | +58.54% | 302B | ||
| +0.37% | +0.37% | +3.33% | +37.27% | 287B | ||
| -0.30% | +1.14% | +38.29% | +72.46% | 252B | ||
| +0.08% | +0.71% | +34.44% | +124.95% | 208B | ||
| Average | +3.92% | -3.99% | +25.51% | +66.33% | 429B | |
| Weighted average by Cap. | +0.54% | +3.26% | +37.70% | +96.50% |
Sector
Annual profits - Rate of surprise
- Stock Market
- Stocks
- IRLAB A Stock
- Company IRLAB Therapeutics AB
Select your edition
All financial news and data tailored to specific country editions
















